Literature DB >> 19894099

Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?

V Sibaud1, J P Delord, C Chevreau.   

Abstract

Sorafenib is a tyrosine kinase inhibitor prescribed primarily for the management of metastatic kidney cancer. It exhibits a good safety profile, but is the cause of a number of dermatological adverse effects. The most common and often the most troublesome is a specific hand-foot skin reaction (HFSR) affecting at least 30% of patients. It occurs predominantly on hyperkeratotic areas of the hands and feet that are subject to chronic pressure, suggesting the role played by repeated subclinical traumas in its pathophysiological mechanism. We report here two new cases of sorafenib-induced HFSR, but associated with identical lesions occurring on specific areas of friction (scar, elbows) and suggestive of a Koebner phenomenon. This provides information about the origin of the palmar and plantar lesions observed with sorafenib.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19894099     DOI: 10.1007/s11523-009-0127-8

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  16 in total

1.  Hand-foot and stump syndrome to sorafenib.

Authors:  Susan E Lai; Timothy Kuzel; Mario E Lacouture
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

2.  The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects.

Authors:  Peter Arne Gerber; Elaine Enderlein; Bernhard Homey
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

3.  Sorafenib-induced eruptive melanocytic lesions.

Authors:  Heidi H Kong; Vincent Sibaud; Maria L Chanco Turner; Tito Fojo; Thomas J Hornyak; Christine Chevreau
Journal:  Arch Dermatol       Date:  2008-06

Review 4.  Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Authors:  Caroline Robert; Jean-Charles Soria; Alain Spatz; Axel Le Cesne; David Malka; Patricia Pautier; Janine Wechsler; Catherine Lhomme; Bernard Escudier; Valérie Boige; Jean-Pierre Armand; Thierry Le Chevalier
Journal:  Lancet Oncol       Date:  2005-07       Impact factor: 41.316

Review 5.  [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].

Authors:  M Deslandres; V Sibaud; C Chevreau; J P Delord
Journal:  Ann Dermatol Venereol       Date:  2008-01       Impact factor: 0.777

6.  Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.

Authors:  C-H Yang; W-C Lin; C-K Chuang; Y-C Chang; S-T Pang; Y-C Lin; T-T Kuo; J-J Hsieh; J W C Chang
Journal:  Br J Dermatol       Date:  2007-12-06       Impact factor: 9.302

7.  Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.

Authors:  Roger von Moos; Beat J K Thuerlimann; Matti Aapro; Daniel Rayson; Karen Harrold; Jalid Sehouli; Florian Scotte; Domenica Lorusso; Reinhard Dummer; Mario E Lacouture; Jürgen Lademann; Axel Hauschild
Journal:  Eur J Cancer       Date:  2008-03-10       Impact factor: 9.162

8.  Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Authors:  Nilofer S Azad; Jeanny B Aragon-Ching; William L Dahut; Martin Gutierrez; William D Figg; Lokesh Jain; Seth M Steinberg; Maria L Turner; Elise C Kohn; Heidi H Kong
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

9.  Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

Authors:  M E Lacouture; L M Reilly; P Gerami; J Guitart
Journal:  Ann Oncol       Date:  2008-06-10       Impact factor: 32.976

10.  Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Authors:  W J Lee; J L Lee; S E Chang; M W Lee; Y K Kang; J H Choi; K C Moon; J K Koh
Journal:  Br J Dermatol       Date:  2009-05-05       Impact factor: 9.302

View more
  6 in total

Review 1.  Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.

Authors:  Maria Vastarella; Gabriella Fabbrocini; Vincent Sibaud
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

2.  HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.

Authors:  Vincent Sibaud; Florence Dalenc; Christine Chevreau; Henri Roché; Jean-Pierre Delord; Loïc Mourey; Jean-Louis Lacaze; Nora Rahhali; Charles Taïeb
Journal:  Oncologist       Date:  2011-09-30

3.  Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®).

Authors:  S Jung; J Sehouli; R Chekerov; F Kluschke; A Patzelt; H Fuss; F Knorr; J Lademann
Journal:  Support Care Cancer       Date:  2017-06-26       Impact factor: 3.603

Review 4.  Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

Authors:  B McLellan; F Ciardiello; M E Lacouture; S Segaert; E Van Cutsem
Journal:  Ann Oncol       Date:  2015-06-01       Impact factor: 32.976

5.  Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.

Authors:  Yuma Nonomiya; Takashi Yokokawa; Kazuyoshi Kawakami; Kazuo Kobayashi; Takeshi Aoyama; Tomomi Takiguchi; Takahito Sugisaki; Kenichi Suzuki; Mitsukuni Suenaga; Takeru Wakatsuki; Kensei Yamaguchi; Yoshikazu Sugimoto; Toshihiro Hama
Journal:  Oncol Res       Date:  2018-06-18       Impact factor: 5.574

6.  Hand-Foot Skin Reaction with Sunitinib: A Rare Case Report with Review of Literature.

Authors:  Suchibrata Das; Alok K Roy; Srutee Barman; Aritra Roy
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.